Drug Trial Radar · NCT01706679
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
Last checked: Nov 19, 2026Latest source record: Nov 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Oct 2012
Primary completion
Feb 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Kythera BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
Conditions
- Healthy
Interventions
ATX-101 (10 mg/ml)Drug
ATX-101 (20 mg/ml)Drug
Moxifloxacin (400 mg)Drug
Placebo vehicle (PBS)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF)Time frame: 2.5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Comprehensive Clinical Development
Miramar, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.